BTAI Projected Dividend Yield
BioXcel Therapeutics Inc ( NASDAQ : BTAI )BioXcel Therapeutics is a clinical stage biopharmaceutical company utilizing artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology. Co.'s two key clinical development programs are BXCL501, an investigational, proprietary, orally dissolving, sublingual thin film formulation of the adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immune activator for the treatment of a rare form of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. 20 YEAR PERFORMANCE RESULTS |
BTAI Dividend History Detail BTAI Dividend News BTAI Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |